Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Sangamo Therapeutics, Inc.”

106 pharma patents match "Sangamo Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 106
Index total 30,257
Page 2 / 5

Quick answer

This filtered view shows 106 pharmaceutical patents matching "Sangamo Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

106 results for “Sangamo Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 11504389

    Tau modulators and methods and compositions for delivery thereof

    Sangamo Therapeutics, Inc. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  2. US 11492643

    Methods and compositions for treatment of a genetic condition

    Sangamo Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  3. US 11452782

    Liver-specific constructs factor VIII expression cassettes and methods of use thereof

    Sangamo Therapeutics, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  4. US 11439666

    Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

    Sangamo Therapeutics, Inc. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  5. US 11421007

    Zinc finger protein compositions for modulation of huntingtin (Htt)

    Sangamo Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  6. US 11401512

    Engineered target specific nucleases

    Sangamo Therapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  7. US 11352631

    Targeted disruption of the T cell receptor

    Sangamo Therapeutics, Inc. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  8. US 11311574

    Methods and compositions for targeted cleavage and recombination

    Sangamo Therapeutics, Inc. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  9. US 11285175

    Targeted disruption of the MHC cell receptor

    Sangamo Therapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  10. US 11235026

    Methods and compositions for modulating PD1

    Sangamo Therapeutics, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  11. US 11236175

    T cell modifying compounds and uses thereof

    Sangamo Therapeutics, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  12. US 11219695

    Methods and compositions for the treatment of Fabry disease

    Sangamo Therapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  13. US 11149321

    Methods and compositions for targeted single-stranded cleavage and targeted integration

    Sangamo Therapeutics, Inc. · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted
  14. US 11123443

    Htt repressors and uses thereof

    Sangamo Therapeutics, Inc. · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  15. US 11110154

    Methods and compositions for treating Huntington's Disease

    Sangamo Therapeutics, Inc. · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted
  16. US 11041174

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  17. US 11040115

    Method for the treatment of lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  18. US 11020492

    Gene correction of SCID-related genes in hematopoietic stem and progenitor cells

    Sangamo Therapeutics, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  19. US 11021696

    Nuclease-mediated regulation of gene expression

    Sangamo Therapeutics, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  20. US 10975393

    Engineered target specific nucleases

    Sangamo Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  21. US 10975375

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  22. US 10968261

    Methods and compositions for genome engineering

    Sangamo Therapeutics, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  23. US 10960085

    Modulation of liver genes

    Sangamo Therapeutics, Inc. · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted
  24. US 10918668

    Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

    Sangamo Therapeutics, Inc. · Granted Feb 16, 2021 · Expires Feb 11, 2041

    granted